Overview

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine
Pemetrexed